Application Nr Approved Date Route Status External Links
ANDA086445 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Tolbutamide Tablets Are Indicated As An Adjunct To Diet To Lower The Blood Glucose In Patients With Non-Insulin-Dependent Diabetes Mellitus (Type Ii) Whose Hyperglycemia Cannot Be Controlled By Diet Alone. In Initiating Treatment For Non-Insulin-Dependent Diabetes, Diet Should Be Emphasized As The Primary Form Of Treatment. Caloric Restriction And Weight Loss Are Essential In The Obese Diabetic Patient. Proper Dietary Management Alone May Be Effective In Controlling The Blood Glucose And Symptoms Of Hyperglycemia. The Importance Of Regular Physical Activity Should Also Be Stressed, And Cardiovascular Risk Factors Should Be Identified And Corrective Measures Taken Where Possible. If This Treatment Program Fails To Reduce Symptoms And/or Blood Glucose, The Use Of An Oral Sulfonylurea Or Insulin Should Be Considered. Use Of Tolbutamide Tablets Must Be Viewed By Both The Physician And Patient As A Treatment In Addition To Diet, And Not As A Substitute For Diet Or As A Convenient Mechanism For Avoiding Dietary Restraint. Furthermore, Loss Of Blood Glucose Control On Diet Alone May Be Transient, Thus Requiring Only Short-Term Administration Of Tolbutamide Tablets. During Maintenance Programs, Tolbutamide Tablets Should Be Discontinued If Satisfactory Lowering Of Blood Glucose Is No Longer Achieved. Judgments Should Be Based On Regular Clinical And Laboratory Evaluations. In Considering The Use Of Tolbutamide Tablets In Asymptomatic Patients, It Should Be Recognized That Controlling The Blood Glucose In Non-Insulin Dependent Diabetes Has Not Been Definitely Established To Be Effective In Preventing The Long-Term Cardiovascular Or Neural Complications Of Diabetes.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Tolbutamide TOLBUTAMIDE ZINC1530703

Comments